atrin pharmaceuticals elects jeffrey m dayno md to board of directors atrin pharmaceuticals elects jeffrey m dayno md to board of directors news provided by atrin pharmaceuticals nov    et share this article doylestown pa nov   prnewswire  atrin pharmaceuticals llc today announced the election of jeffrey m dayno md chief medical officer of egalet corporation to the atrin board of directors  dr jeffrey dayno joins the atrin board with an  year track record of success building and leading clinical development and medical affairs teams at both global and emerging biopharmaceutical companies said oren gilad phd atrin pharmaceuticals president and chief executive officer jeff brings to our board a keen perspective on all aspects of pharmaceutical medicine including clinical development strategy and trial design as well as regulatory strategy and experience interacting with the fda that will serve our company well as we prepare to advance our novel atr inhibitors into clinical development i am very pleased to welcome jeff to the atrin board of directors prior to joining egalet a specialty pharmaceutical company focused on developing and commercializing innovative treatments for pain and other conditions  dr dayno was vice president global medical affairs at viropharma inc where he was also involved in early stage development for rare diseases  prior to viropharma dr dayno served as the chief medical officer at labopharm inc a drug delivery technology company based in montreal canada where he first started working in the field of abusedeterrent opioid product development before labopharm he was vice president of global medical affairs at cephalon inc and established the phase b late stage clinical development program  dr dayno started his career in the pharmaceutical industry in  at merck  co inc where he spent  years in positions of increasing responsibility in the medical and scientific affairs division before moving into leadership roles in the pharmaceutical and biotechnology industry he spent  years in academic and clinical medicine involved in patient care teaching and clinical research dr dayno earned his medical degree from temple university school of medicine completed his residency in neurology at temple university hospital and did a fellowship in stroke and cerebrovascular disorders at henry ford hospital  he is a former chairman of the philadelphia stroke council and since  has been a member of the board of visitors of the lewis katz school of medicine at temple university about atrin pharmaceuticals atrin pharmaceuticals is a privately held biopharmaceutical company based in doylestown pa that aims to change the way cancer is being treated the company is engaged in the discovery and development of innovative treatments for cancer atrins most advanced program is focused on a new class of compounds that are highly specific inhibitors of atr a key mediator of dna repair atrin is further assembling a pipeline of additional drug candidates identified via the companys proprietary human cellbased highthroughput screening platform atrize™ applicable to both drug discoverydevelopment and the evaluation of patientspecific treatments atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells for more information on the company please visit our website at httpatrinpharmacom logo  httpphotosprnewswirecomprnhlogo   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesatrinpharmaceuticalselectsjeffreymdaynomdtoboardofdirectorshtml source atrin pharmaceuticals related links httpatrinpharmacom oct    et preview atrin pharmaceuticals appoints gerhard j sperl phd as vice president chemistry manufacturing and controls my news release contains wide tables view fullscreen you just read atrin pharmaceuticals elects jeffrey m dayno md to board of directors news provided by atrin pharmaceuticals nov    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search jeffrey m dayno md executive profile  biography  bloomberg july    am et pharmaceuticals company overview of egalet corporation snapshotpeople  overviewboard memberscommittees executive profile jeffrey m dayno mdchief medical officer egalet corporationagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr jeffrey m dayno md has been the chief medical officer at egalet corporation since july   dr dayno served as the president at labopharm usa inc he served as chief medical officer at labopharm inc since may   where he was a member of several senior rd leadership teams he was responsible for leading the clinical activities for labopharms drug development programs as well as overseeing its medical affairs functions including medical information  and pharmacovigilance for all commercialized products he was vice president of medical affairs at cephalon inc from  to  dr dayno started his career in the pharmaceutical industry in  at merck  co inc dr dayno spent ten years in clinical and academic medicine before moving into the pharmaceutical industry he served as vice president of global medical affairs at viropharma from august  to may  where he was a member of several senior rd leadership teams he has  years of senior track record of senior pharmaceutical industry experience at both global and emerging biopharmaceutical companies in the realm of medical affairs and pharmaceutical medicine during which time he oversaw and provided strategic guidance to clinical development programs interacted with regulatory authorities around the world built and led medical affairs departments and orchestrated the integration of these functions in support of commercial franchises as a practicing neurologist dr dayno has clinical experience caring for chronic pain patients he has held a number of clinical appointments including clinical assistant professor of neurology jefferson medical college and medical director of the jefferson health systems stroke center network he has served as principal investigator on numerous clinical trials has published and lectured extensively on various topics in the field of neurology and is a peer reviewer for several scientific journals dr dayno joined labopharm from cephalon inc where he served as vice president of medical services and oversaw a team of medical directors in support of commercial franchises prior to his tenure at cephalon he spent seven years with merck  co inc in increasingly senior medical services positions culminating in his role as senior director medical services us medical  scientific affairs he has been director at atrin pharmaceuticals llc since november   he held a number of clinical appointments including clinical assistant professor of neurology jefferson medical college philadelphia and medical director jefferson health systems stroke center network philadelphia he is a member of the board of visitors of temple university school of medicine and was the chairman of the philadelphia stroke council dr dayno received his bachelors degree from trinity college and his medical degree from temple university he did his residency in neurology at temple university hospital did a fellowship in stroke and cerebrovascular disorders at henry ford hospital and was board certified in neurologyread full background corporate headquarters  lee roadwayne pennsylvania united statesphone fax  board members memberships presentdirectoratrin pharmaceuticals llc education md temple universitybachelors degree trinity college other affiliations labopharm inctemple universitytrinity collegeatrin pharmaceuticals llc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationjames e brown dvmcofounder chief executive officer president and directordurect corporationknasrat hakim chairman of the board president  chief executive officerelite pharmaceuticals incmmark a sirgo pharmdvice chairman chief executive officer and presidentbiodelivery sciences international inckstephen j farr phdcofounder chief executive officer president and directorzogenix inckvincent j angotti ceo interim cfo  directoracelrx pharmaceuticals inccompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact egalet corporation please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close egalet appoints jeffrey m dayno md as chief medical officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street egalet appoints jeffrey m dayno md as chief medical officer globenewswire jul    am edt wayne pa july   globe newswire  egalet corporation nasdaqeglt egalet today announced the appointment of jeffrey m dayno md as chief medical officer cmo dr dayno will be responsible for leading egalets clinical development programs as well as overseeing the activities in regulatory affairs pharmacovigilance and medical affairs dr dayno will begin july  we would like to welcome jeff to our management team at this critical time as we move our lead abusedeterrent product candidate egalet through the final phase of development and plan to file an nda in the fourth quarter said bob radie president and ceo jeffs deep global pharmaceutical and medical affairs experience in the neurology and pain areas will be invaluable as we advance our product candidates develop our medical affairseducation strategies and evolve our commercial organization we also would like to thank roland gerritsen van der hoop md phd our acting cmo for his guidance over the past few years as he transitions to become an advisor to egalet dr dayno spent ten years in clinical and academic medicine before moving into the pharmaceutical industry he most recently served as vice president global medical affairs at viropharma a pharmaceutical company which was bought by shire in  where he was a member of several senior rd leadership teams prior to joining viropharma dr dayno held the position of chief medical officer for labopharm inc a canadian biotechnology company where he oversaw all of the rd activities and gained valuable experience working in the area of abusedeterrent opioid product development before labopharm he was the vice president medical services at cephalon where he directed cephalons phase b clinical development programs dr dayno started his career in pharma at merck  co inc where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division in total he has  years of experience in pharmaceutical medicine during which time he oversaw and provided strategic guidance to clinical development programs interacted with regulatory authorities around the world built and led medical affairs departments and orchestrated the integration of these functions in support of commercial franchises  if you liked this article you might like  undervalued biotech stocks two are turnaround stories and two are oversold bret jensen jun    am edt  beatendown biotechs that should head up synergy pharmaceuticals trevena and egalet seem to have worstcase scenarios priced into them bret jensen jun    am edt  questions from the biotech mailbag a look at how lawsuits and fda changes could impact the industry bret jensen mar    am edt egalet makes fridays biotech mailbag why the name is sagging and what it will take to spur the sector higher bret jensen mar    am est trending amazon falls obamacare repeal fails   things you must know before the market opens i believe ugly would be the proper term for the selloff market recon stock futures lower on amazons earnings disappointment us economy grows  in q dont buy the hype twitter isnt dead yet att verizon prove their worth exxon mobil stock tanks on earnings miss advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers atrin pharmaceuticals elects jeffrey m dayno md to board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       atrin pharmaceuticals elects jeffrey m dayno md to board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs doylestown pa nov   prnewswire  atrin pharmaceuticals inc today announced the election of jeffrey m dayno md chief medical officer of egalet corporation to the atrin board of directors jeffrey dayno joins the atrin board with an  years of senior track record of senior pharmaceutical industry experience at both global and emerging biopharmaceutical companies in the realm of medical affairs said oren gilad phd atrin pharmaceuticals president and chief executive officer he brings to our board a keen perspective on all aspects of pharmaceutical medicine clinical development strategy and trial design and drug regulatory affairs that will serve our company well as we prepare to advance our novel atr inhibitors into clinical development i am very pleased to welcome jeff to the atrin board of directorsprior to joining egalet a specialty medical pharmaceutical company focused on innovative treatments for pain in july  dr dayno was vice president global medical affairs at viropharma inc from august  to may  prior to joining viropharma dr dayno was the chief medical officer at labopharm inc a drug delivery technology company based in montreal canada where he first started working in the field of abusedeterrent opioid product development before labopharm he was vice president of medical affairs at cephalon inc from  to  dr dayno started his career in the pharmaceutical industry in  at merck  co inc where he spent  years in positions of increasing responsibility in the medical and scientific affairs division before moving into leadership roles in the pharmaceutical and biotechnology industry he spent  years in academic and clinical medicine involved in patient care teaching and clinical research dr dayno earned his medical degree from temple university school of medicineabout atrin pharmaceuticalsatrin pharmaceuticals is a privately held biopharmaceutical company based in doylestown pa that aims to change the way cancer is being treated the company is engaged in the discovery and development of innovative treatments for cancer atrins most advanced program is focused on a new class of compounds that are highly specific inhibitors of atr a key mediator of dna repair atrin is further assembling a pipeline of additional drug candidates identified via the companys proprietary human cellbased highthroughput screening platform atrize applicable to both drug discoverydevelopment and the evaluation of patientspecific treatments atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells for more information on the company please visit our website at httpatrinpharmacomlogo  httpphotosprnewswirecomprnhlogoto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesatrinpharmaceuticalselectsjeffreymdaynomdtoboardofdirectorshtmlsource atrin pharmaceuticals inc read at biospacecom related news atrin pharmaceuticals appoints gerhard j sperl phd as vice president chemistry manufacturing and controls biogen biib taps former spark therapeutics once exec and a finance vet for hemophilia spinoff company bioverativ martin shkreli makes good on promise shares secret wutang clan songs after trump win meet the woman thats helming bay areas calithera biosciences cala celgene celg exec may be a dark horse candidate for donald trumps secretary of health and human services fortress biotech cndo forms cellvation taps forest frx life technologies life alum as interim ceo  biopharma influencers likely to be on trump’s transition team trump promises to reform the fda in postelection mission statement celgene celg exec out as trump puts vice president elect leader of transition effort cipher pharma dndto announces management change please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • atrin pharmaceuticals   • biotechpharma  personnel                 microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft egalet corp appoints dr jeffrey dayno chief medical officer  vistatoday contact us our publications montcotoday – montgomery county pivottoday – delaware county outwordtoday – lgbt philly suburbs about vistatoday contact us our publications montcotoday – montgomery county pivottoday – delaware county outwordtoday – lgbt philly suburbs about vistatoday contact us our publications montcotoday – montgomery county pivottoday – delaware county outwordtoday – lgbt philly suburbs about vistatoday contact us our publications montcotoday – montgomery county pivottoday – delaware county outwordtoday – lgbt philly suburbs about vistatoday todays headlines check out the average credit score of each town in chester county curtain finally lifts on phoenixville’s expanded colonial theatre henderson high school teacher leads national march for public education chester county leadership – vince pompo attorney lamb mcerlane vista careers – evolve ip od chatter motivating employees when the boss is away chester county briefly july  coatesville ready for a resurgence akin to west chester’s phoenixville’s after tasting sip of success in virginia lumi brings organic juice business to malvern octorara super announces this school year will be his last home commerce pharma  biotech egalet corp appoints dr jeffrey dayno chief medical officer egalet corp appoints dr jeffrey dayno chief medical officer posted by contributorposted date july   jeffrey m dayno md courtesy of wwwexlpharmacom wayne pa – egalet corporation the wayne pharmaceutical firm working to bring abusedeterrent pain medications to market has appointed dr jeffrey m dayno chief medical officer dr dayno will be responsible for leading egalet’s clinical development programs and will oversee regulatory and medical affairs and pharmacovigilance “we would like to welcome jeff to our management team at this critical time as we move our lead abusedeterrent product candidate egalet through the final phase of development and plan to file an nda in the fourth quarter” said bob radie president and ceo  “jeff’s deep global pharmaceutical and medical affairs experience in the neurology and pain areas will be invaluable as we advance our product candidates develop our medical affairseducation strategies and evolve our commercial organization” radie also thanked dr roland gerritsen van der hoop acting cmo for his guidance over the past few years he is transitioning to an advisory role at egalet dr dayno spent  years in clinical and academic medicine before moving into the pharmaceutical industry  he most recently served as vice president global medical affairs at viropharma a pharmaceutical company which was bought by shire in  he was a member of several senior rd leadership teams a former practicing neurologist dr dayno has clinical experience caring for chronic pain patients  dr dayno has held a number of clinical appointments including clinical assistant professor of neurology jefferson medical college and medical director of the jefferson health systems stroke center network he has served as principal investigator on numerous clinical trials has published and lectured extensively on various topics in the field of neurology and has been a peer reviewer for several scientific journals “given the need for abuse deterrent pain medications and the potential seen with egalet’s lead abusedeterrent product candidates i am thrilled to be a part of the egalet team” said dr dayno “i look forward to working with the team to achieve the company’s mission of helping to ensure access to effective medications for individuals living with chronic pain while protecting physicians families and communities” dr dayno is also currently a member of the board of visitors of temple university school of medicine and was a former chairman of the philadelphia stroke council top photo credit nikongirl via photopin cc  follow us on twitter like us on facebook tags bob radiedr jeffrey m daynodr roland gerritsen van der hoopegalet corporationfeaturedwayne like  tweet share  share  share  comments comments previous vishay wins european supplier excellence award next bob casey promotes mushrooms as healthy school lunch solution related articles malvern’s endo to unload its mexico city subsidiary for  million july   malvern’s onspira therapeutics raises  million in private stock sale july   malvern’s recro pharma buys nonopioid pain treatments from ivy league college july   chester county upcoming events aug cccbi summer golf clinic view details  pm –  pm aug wcccc chamber night at the reading phils view details  pm –  pm aug coatesville back to school prepare for success view details  pm –  pm aug scccc nd annual scolarship golf tournament  dinner view details  am –  pm aug prcc august monthly membership meeting view details  am –  pm view all events top posts despite homelessness coatesville sprinter finds refuge — an  views chester county leadership – vince pompo attorney lam  views coatesville ready for a resurgence akin to west chester’s p  views changes coming to paoli train station on monday  views new ceo of west chester’s lasko holdings optimistic about co  views west chester siblings create organic weed killer  views affiliate partners chamber partners copyright   american community journals llc website design  implementation by miller designworks rezultati  dayno jeffrey m skip to content toggle navigation vufind umnik katalog ukm eds discovery service katalog ukm  naslov  avtor  tema  signatura  isbnissn  oznaka raziskovalni vodiči eds  naslov  avtor išči napredno ohrani moje filtre expandfulltext išči dayno jeffrey m pokaži    od  za iskanje dayno jeffrey m čas poizvedbe s rezultatov na stran       razvrsti po padajočem datumu po rastočem datumu po pomembnosti title view  brief view  detailed view  izberi stran  z izbranim  academic journal human abuse potential of an abusedeterrent ad extendedrelease er morphine product candidate morphineader injectionmolded tablets versus extendedrelease morphine administered orally in nondependent recreational opioid users authors smith michael d webster lynn r lawler john lindhardt karsten dayno jeffrey m source pain medicine pain med may   p publication type article prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal the alerrt® instrument a quantitative measure of the effort required to compromise prescription opioid abusedeterrent tablets authors cone edward j buchhalter august r lindhardt karsten elhauge torben dayno jeffrey m source american journal of drug  alcohol abuse may vol  issue  p p subject terms opioid abuse drug abuse injection molding dosage of drugs companyentity united states food  drug administration prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal poster  bioequivalence and food effect of a novel abusedeterrent ad extendedrelease er morphine product candidate compared with a currently available nonad er morphine product authors dayno jeffrey m lawler john niebler gwendolyn lindhardt karsten source in  aapmr annual assembly abstracts pmr september   supplements prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal poster  pharmacodynamic effects from a category  intranasal human abuse potential study of an abusedeterrent extendedrelease morphine product candidate in nondependent recreational opioid users authors webster lynn r smith michael d lawler john lindhardt karsten dayno jeffrey m source in  aapmr annual assembly abstracts pmr september   supplementss prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal poster  pharmacodynamic effects from a category  oral human abuse potential study of an abusedeterrent extendedrelease morphine product candidate in nondependent recreational opioid users authors smith michael d webster lynn r lawler john lindhardt karsten dayno jeffrey m source in  aapmr annual assembly abstracts pmr september   supplements prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal poster  dissolution studies in the presence of alcohol with an abusedeterrent extendedrelease morphine product candidate authors elhauge torben kristensen lene dayno jeffrey m lindhardt karsten source in  aapmr annual assembly abstracts pmr september   supplements prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal acute stroke units authors dayno jeffrey m a b  mansbach harry h a b source in journal of stroke and cerebrovascular diseases   prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal the alerrt® instrument a quantitative measure of the effort required to compromise prescription opioid abusedeterrent tablets authors cone ej a pinneyassociates  bethesda  md  usa buchhalter ar a pinneyassociates  bethesda  md  usa lindhardt k b egalet corporation  wayne  pa  usa elhauge t b egalet corporation  wayne  pa  usa dayno jm b egalet corporation  wayne  pa  usa source the american journal of drug and alcohol abuse am j drug alcohol abuse  may vol   pp  date of electronic publication  feb  publication type journal article journal info publisher informa healthcare country of publication england nlm id  publication model printelectronic cited medium internet issn  electronic linking issn  nlm iso abbreviation am j drug alcohol abuse subsets in process prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal human abuse potential of an abusedeterrent ad extendedrelease er morphine product candidate morphineader injectionmolded tablets vs extendedrelease morphine administered intranasally in nondependent recreational opioid users authors webster lr pra health sciences salt lake city utah websterlynnprahscom smith md pra health sciences salt lake city utah lawler j egalet corporation wayne pennsylvania usa lindhardt k egalet corporation wayne pennsylvania usa dayno jm egalet corporation wayne pennsylvania usa source pain medicine malden mass pain med  sep  date of electronic publication  sep  publication type journal article journal info publisher published by oxford university press on behalf of the american academy of pain medicine country of publication england nlm id  publication model printelectronic cited medium internet issn  electronic linking issn  nlm iso abbreviation pain med prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal treating early versus treating mild timing of migraine prescription medications among patients with diagnosed migraine authors foley kathleen a cady roger martin vincent adelman james diamond merle bell christopher f dayno jeffrey m hu x henry source headache the journal of head  face pain may vol  issue  p p subject terms migraine patients headache physicians pain drugs prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal what do patients with migraine want from acute migraine treatment authors lipton richard b hamelsky sandra w dayno jeffrey m source headache the journal of head  face pain jan supplement  vol  p p  charts  graphs subject terms patients migraine treatment attitude psychology prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal migraine treatment authors young william b silberstein stephen d dayno jeffrey m source seminars in neurology  vol  issue  p p prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal migrainerelated stroke versus migraineinduced stroke authors dayno jeffrey m silberstein stephen d source headache the journal of head  face pain jul vol  issue  p p prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal evaluation of the safety of modafinil for treatment of excessive sleepiness authors roth t henry ford sleep disorders center detroit mi  usa trothhfhsorg schwartz jr hirshkowitz m erman mk dayno jm arora s source journal of clinical sleep medicine jcsm official publication of the american academy of sleep medicine j clin sleep med  oct  vol   pp  publication type journal article research support nonus govt journal info publisher american academy of sleep medicine country of publication united states nlm id  publication model print cited medium print issn  print linking issn  nlm iso abbreviation j clin sleep med subsets medline mesh terms wakefulnessdrug effects benzhydryl compoundsadverse effects  central nervous system stimulantsadverse effects  disorders of excessive somnolencedrug therapy  sleep apnea obstructivedrug therapy adult  benzhydryl compoundsadministration  dosage  central nervous system stimulantsadministration  dosage  continuous positive airway pressure  female  headachechemically induced  humans  infectionetiology  male  middle aged  nauseachemically induced  randomized controlled trials as topic  severity of illness index  surveys and questionnaires  treatment outcome prikaži qr kodo dodaj v priljubljene shranjeno v  academic journal comparison of chromogenic and elisa functional c inhibitor tests in diagnosing hereditary angioedema authors li hh institute for asthma and allergy chevy chase md electronic address hlallergyasthmaus busse p department of medicine division of clinical immunology mount sinai school of medicine new york ny lumry wr allergy and asthma research association research center dallas tex frazerabel a complement laboratory national jewish health denver colo levy h viropharma incorporated part of the shire group of companies exton pa steele t viropharma incorporated part of the shire group of companies exton pa dayno j viropharma incorporated part of the shire group of companies exton pa riedl m department of medicine division of rheumatology allergy and immunology university of californiasan diego la jolla calif source the journal of allergy and clinical immunology in practice j allergy clin immunol pract  marapr vol   pp  date of electronic publication  oct  publication type comparative study journal article research support nonus govt journal info publisher elsevier inc country of publication united states nlm id  publication model printelectronic cited medium internet issn  electronic nlm iso abbreviation j allergy clin immunol pract subsets medline mesh terms angioedemas hereditarydiagnosis  complement c inhibitor proteinanalysis adolescent  adult  aged  angioedemas hereditaryblood  angioedemas hereditaryepidemiology  child  child preschool  enzymelinked immunosorbent assay  female  humans  male  middle aged  young adult prikaži qr kodo dodaj v priljubljene shranjeno v izberi stran  z izbranim iskalna orodja rss — pošljite iskanje po emailu — shrani iskanje refine results catalog onlyfull textpeer reviewedalso search within the full text of the articles format  academic journals tema  morphine  migraine  patients  patient satisfaction  abuse deterrent  administration of drugs več   attitude psychology  blind experiment  controlled release preparations  crossover trials  decision making  dosage of drugs  drug abuse  drugs  early treatment  end points  extended release  headache  injection molding  opioid abuse  opioids  pain  patient  physicians  placebos medicine  randomized controlled trials  substance abuse  prevention  survey  treatment delay  triptans  united states food  drug administration  visual analog scale  drug liking  migraine treatment  pharmacodynamics  tampering  angioedemas hereditary  benzhydryl compounds  central nervous system stimulants  complement c inhibitor protein  disorders of excessive somnolence  drug administration schedule  drugs  physiological effect  human abuse potential  migraine  treatment  migraine disorders  migraine medication  migraine with aura  patient compliance  physician preferences manj  izdajatelj  wileyblackwell  elsevier inc  elsevier  oxford university press  usa  taylor  francis ltd  published by oxford university press on behalf of the american academy of pain medicine več   wiley  american academy of sleep medicine  georg thieme verlag stuttgart  informa healthcare manj  izdano v  headache the journal of head  face pain  pain medicine  pm r the journal of injury function and rehabilitation  pmr  american journal of drug  alcohol abuse  headache več   pain medicine malden mass  american journal of drug and alcohol abuse  journal of allergy and clinical immunology in practice  journal of clinical sleep medicine jcsm official publication of the american academy of sleep medicine  journal of stroke and cerebrovascular diseases  seminars in neurology manj  jezik  english publicationyear       source  medline  complementary index  sciencedirect  academic search elite  academic search complete  cinahl with full text leto izdaje od za ×   nalaganje egalet appoints jeffrey m dayno md as chief medical officer nasdaqeglt english français register sign in egalet appoints jeffrey m dayno md as chief medical officer july    et  source egalet corporation wayne pa july   globe newswire  egalet corporation nasdaqeglt egalet today announced the appointment of jeffrey m dayno md as chief medical officer cmo dr dayno will be responsible for leading egalets clinical development programs as well as overseeing the activities in regulatory affairs pharmacovigilance and medical affairs dr dayno will begin july  we would like to welcome jeff to our management team at this critical time as we move our lead abusedeterrent product candidate egalet through the final phase of development and plan to file an nda in the fourth quarter said bob radie president and ceo jeffs deep global pharmaceutical and medical affairs experience in the neurology and pain areas will be invaluable as we advance our product candidates develop our medical affairseducation strategies and evolve our commercial organization we also would like to thank roland gerritsen van der hoop md phd our acting cmo for his guidance over the past few years as he transitions to become an advisor to egalet dr dayno spent ten years in clinical and academic medicine before moving into the pharmaceutical industry he most recently served as vice president global medical affairs at viropharma a pharmaceutical company which was bought by shire in  where he was a member of several senior rd leadership teams prior to joining viropharma dr dayno held the position of chief medical officer for labopharm inc a canadian biotechnology company where he oversaw all of the rd activities and gained valuable experience working in the area of abusedeterrent opioid product development before labopharm he was the vice president medical services at cephalon where he directed cephalons phase b clinical development programs dr dayno started his career in pharma at merck  co inc where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division in total he has  years of experience in pharmaceutical medicine during which time he oversaw and provided strategic guidance to clinical development programs interacted with regulatory authorities around the world built and led medical affairs departments and orchestrated the integration of these functions in support of commercial franchises  as a former practicing neurologist dr dayno has clinical experience caring for chronic pain patients dr dayno has held a number of clinical appointments including clinical assistant professor of neurology jefferson medical college and medical director of the jefferson health systems stroke center network he has served as principal investigator on numerous clinical trials has published and lectured extensively on various topics in the field of neurology and has been a peer reviewer for several scientific journals given the need for abuse deterrent pain medications and the potential seen with egalets lead abusedeterrent product candidates i am thrilled to be a part of the egalet team said dr dayno i look forward to working with the team to achieve the companys mission of helping to ensure access to effective medications for individuals living with chronic pain while protecting physicians families and communities   dr dayno received his bachelors degree from trinity college and his medical degree from temple university he did his residency in neurology at temple university hospital did a fellowship in stroke and cerebrovascular disorders at henry ford hospital and was board certified in neurology dr dayno is currently a member of the board of visitors of temple university school of medicine and was a former chairman of the philadelphia stroke council about egalet egalets mission is to help ensure access to effective medications for individuals living with chronic pain while protecting physicians families and communities from the burden of abuse prescription opioid abuse has reached epidemic levels in the united states with  million current prescription drug abusers and drug abuse is now the leading cause of accidental death in the united states with the majority of opioids abused in the united states originating from a prescription and most often coming from a friend or family a safeguard against the unexpected is needed  egalet is committed to bringing peace of mind to the patients and physicians it serves by offering abusedeterrent pain medications  using the proprietary guardian™ technology the company has a pipeline of clinicalstage opioidbased product candidates that are specifically designed to deter abuse by physical and chemical manipulation  the guardian technology is customized to resist specific routes of abuse that often occur with the underlying active pharmaceutical ingredient  the companys lead program egalet an abusedeterrent extendedrelease oral morphine formulation is in development for the management of pain severe enough to require daily aroundtheclock opioid treatment and for which alternative treatments are inadequate  it was designed to resist common methods of abuse including one of the most common routes for morphine via injection with no abusedeterrent formulations of morphine currently available egalet which is in pivotal studies if approved could fill a significant unmet need in the marketplace egalet plans to file an nda for this product candidate in the fourth quarter of   egalet an abusedeterrent extendedrelease oral oxycodone formulation is in development for the management of pain severe enough to require daily aroundtheclock opioid treatment and for which alternative treatments are inadequate egalet was designed to resist common methods of abuse including crushing and snorting the most common route of abuse for oxycodone egalet plans to file an nda for egalet in the first half of   egalet entered into a collaboration with shionogi in november of  to develop abusedeterrent hydrocodone based products egalets guardian™ technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles egalet has a strong ip position of  granted patents and is continually enhancing its proprietary position visit wwwegaletcom for more information safe harbor statements included in this press release that are not historical in nature are forwardlooking statements within the meaning of the private securities litigation reform act of  these forwardlooking statements are based on managements current expectations and are subject to known and unknown uncertainties and risks actual results could differ materially from those discussed due to a number of factors including but not limited to the success of our clinical trials our ability to obtain regulatory approval of our product candidates competitive factors general market conditions and other risks factors described in egalets filings with the united states securities and exchange commission egalet assumes no obligation to update or revise any forwardlookingstatements contained in this press release whether as a result of new information or future events except as may be required by law investor and media contact biotechcomm e blair clarkschoeb tel  email related articles other press releases by egalet corporation egalet announces positive topline results from oral human abuse liability study of abusedeterrent morphine egalet january    egalet appoints deanne f melloy as chief commercial officer january    egalet acquireslicenses two innovative approved pain products january    egalet to present at the stifel  healthcare conference on november  november    egalet announces update on clinical development plan for abusedeterrent morphine egalet september     other news releases in directors and officers in the last  days profile egalet corporation   subscribe via rss  subscribe via atom  javascript wayne pennsylvania united states   httpwwwegaletcom contact data investor and media contact biotechcomm e blair clarkschoeb tel  email contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files egalet corporation logo logo url  copy the link below formats available original medium small tags health medical management changes newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved